Stock Alert for Marshall Edwards Inc. (MSHL)
  • Small-Cap Stock Spotlight: EMCORE Corp. (EMKR) Shares Up following Q4 Results
  • Small-Cap Stock Spotlight: Tengion Inc. (TNGN)
  • " />

    Small-Cap Stock Spotlight: New Patent Announcement Drives Marshall Edwards (MSHL) Shares Up 11%

    Small-Cap Stock Spotlight: New Patent Announcement Drives Marshall Edwards (MSHL) Shares Up 11%

    Share of Marshall Edwards Inc.  (NASDAQ: MSHL) rose 11.3% to $1.18 Tuesday after the San Diego, CA-based drug developer said it was awarded a key patent for compositions of its lead oncology drug candidates. The stock reached an intraday high of $1.78 as volume swelled to over 976 K shares.

    The U.S. Patent and Trademark Office issued patent number 8,080,675 to Marshall Edwards, which covers a number of the Company’s isoflavone-based compounds, including lead oncology drug candidates ME-143 and ME-344, and their pharmaceutical compositions. The patent is expected to provide protection until March 2027.

    Daniel P. Gold, Ph.D., president and CEO of Marshall Edwards, commented that this patent demonstrates the company’s commitment to further strengthening the intellectual property portfolio it acquired earlier this year, which will be essential for partnering any of its drug candidates and enhancing shareholder value.

    In May of this year, Marshall Edwards completed the acquisition of its isoflavone-based intellectual property portfolio, including worldwide rights to ME-143 and ME-344, from Novogen Ltd. The portfolio now includes 11 issued U.S. patents, at least 14 U.S. patent applications, at least 40 issued foreign patents and at least 80 foreign patent applications.

    Founded in 2000, Marshall Edwards is focused on the clinical development of novel therapeutics targeting cancer metabolism lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism.

    The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143. The Company initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors in September 2011, and expects final data from the trial by the second quarter of 2012. The second program is a family of mitochondrial inhibitors that includes lead candidate ME-344.

    The company is currently conducting the necessary pre-clinical animal toxicity studies to support submission of an Investigational New Drug application for ME-344 in the first quarter of next year.

    Shares of Marshall Edwards have gained 9.3% in the last five days, though the stock lost 1.7% in the last month.  Year-to-date, the stock is up 49.1%.

    Leave a Reply

    Your email address will not be published. Required fields are marked *